BÜHLMANN fCAL® ELISA Diagnosis Citations Archives - Buhlmann Diagnostics Corp

Category: BÜHLMANN fCAL® ELISA Diagnosis Citations

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use.
Health Canada License: 80726
(Intended Use: The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.)

Clinical Accuracy of the BÜHLMANN fCAL® ELISA in the Differentiation of IBD from IBS

BÜHLMANN fCAL® ELISA Citation Berinstein, J. et al.  The Clinical Accuracy of the BÜHLMANN fCAL® ELISA in the Differentiation of Inflammatory Bowel Disease from Irritable Bowel Syndrome: A Multi-Center Prospective Case-Control Study.  Crohn's & Colitis 360 (2019).  DOI: https://doi.org/10.1093/crocol/otz037. [Accepted Manuscript] Highlight from this Publication “The BÜHLMANN fCAL ELISA demonstrates excellent discriminating between IBD and IBS.”
Continue Reading

Are We Exposing Patients with a Mildly Elevated Faecal Calprotectin to Unnecessary Investigations?

BÜHLMANN fCAL®ELISA Citation: Seenan, JP, Thomson, Rankin K, Smith K, Gaya DR. Are we exposing patients with a mildly elevated faecal calprotectin to unnecessary investigations? Gastroenterology. 2014 Frontline Gastroenterol doi:10.1136/flgastro-2014-100467.

Highlight from this Publication:

“...we propose an alternative diagnostic approach of repeating the FC after 6-8 weeks in patients with values of 100-200 µg/g.”
Continue Reading

Diagnostic Accuracy and Clinical Application of Faecal Calprotectin in Adult Patients Presenting with Gastrointestinal Symptoms in Primary Care

BÜHLMANN fCAL®ELISA Citation Pavlidis, P ,Pavlidis P, Chedgy FJ, Tibble JA. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care, Scandinavian Journal of Gastroenterology. 2013 Sep;48(9):1048-54. doi: 10.3109/00365521.2013.816771.

Highlight from this Publication

“This study provides the first evidence on the use of fCal [BÜHLMANN fCAL® ELISA]testing in primary care…..to be used as part of the pathway for management of patients with suspected IBS.”
Continue Reading

Estimation of the Possible Economic Effects of Pre-Endoscopic Screening with F-calprotectin, Clinical Biochemistry

BÜHLMANN fCAL® ELISA Citation: Mindemark, M. & Larsson, A. Ruling out IBD: Estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin, Clinical Biochemistry. Clin Biochem. 2012 May;45(7-8):552-5. doi: 10.1016/j.clinbiochem.2011.10.015.

Highlights from this Publication:

“The estimated demand for colonoscopies was reduced by 50% to 67%. This corresponded to a cost avoidance of approximately up toa cost avoidance of approximately up to €2.13 million.”
Continue Reading